NIH Conflict Of Interest Reg Attracts Criticism From Transparency Advocates
This article was originally published in The Gray Sheet
A new upgrade to the National Institutes of Health’s1995 regulations overseeing researcher conflict of interests is intended as “an insurance plan” against potential trouble downstream, NIH Director Francis Collins says. But a key change in the final rule compared to an earlier proposal is attracting criticism from transparency advocates.
You may also be interested in...
A government watchdog group is worried that the White House Office of Management and Budget is about to take the teeth out of the National Institute of Health's proposed new conflict of interest rule.
Toxicity testing is one area in which NIH Director Francis Collins expects the proposed National Center for Advancing Translational Science to help industry speed up drug development.
CMS's Office of Policy will issue a proposed rule as early as this summer explaining how companies should implement the physician payment reporting requirements authorized in the health reform law, an agency official said.